Mdxhealth to acquire Exosome Diagnostics from Bio-Techne Corporation.

Mdxhealth, a biotechnology company, agreed to acquire Exosome Diagnostics, a company specializing in the ExoDx prostate test, from Bio-Techne Corporation, a global manufacturer and supplier of high-quality reagents. Financial terms are not disclosed. "Mdxhealth is the ideal acquirer of our ExoDx Prostate test and CLIA-certified laboratory. Mdxhealth has made several strategic moves over the past few years to position the company as a leader in urology and prostate cancer diagnostics. The addition of ExoDx Prostate to their portfolio accelerates their leadership in this market," Kim Kelderman, Bio-Techne President and Chief Executive Officer.